CTI Biopharma Corp, Inc. (NASDAQ: CTIC), relating to its proposed sale to Swedish Orphan Biovitrum AB. Under the terms of the agreement, CTIC shareholders are expected to receive $9.10 in cash per share they own.
CTI Biopharma Corp, Inc. (NASDAQ: CTIC), relating to its proposed sale to Swedish Orphan Biovitrum AB. Under the terms of the agreement, CTIC shareholders are expected to receive $9.10 in cash per share they own.